TIM3 comes of age as an inhibitory receptor
By Yochai Wolf, A. Anderson, V. Kuchroo. Nature reviews. Immunology, 2019
810 citations recorded by the source corpus.
Subfields: Immunology, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/57a4e2fcc48884e0f6e3f786a2b100288406d317
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- The future of cancer immunotherapy: microenvironment-targeting combinations (2020, background): “Combinations of TIM-3 inhibition with anti-CTLA-4 or anti-PD-1 have demonstrated preclinical efficacy, and numerous clinical trials are ongoing.(28,33,35) Fig.”